Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study

[1]  Sebastian Schneeweiss,et al.  Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis , 2007 .

[2]  Jeffrey N Katz,et al.  Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[3]  J. Avorn,et al.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[4]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[5]  D. Zochodne,et al.  Neurological complications of infliximab. , 2006, Journal of Rheumatology.

[6]  D. M. van der Heijde,et al.  The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28 , 2006, Arthritis research & therapy.

[7]  J. Avorn,et al.  The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28 , 2006, Arthritis research & therapy.

[8]  J. Avorn,et al.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[9]  S. Schneeweiss,et al.  Performance of a rheumatoid arthritis records-based index of severity. , 2005, The Journal of rheumatology.

[10]  J. Avorn,et al.  Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel. , 2005, Arthritis and rheumatism.

[11]  H. Olsson,et al.  Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas , 2005, Annals of the rheumatic diseases.

[12]  P. Laippala,et al.  Death rates and causes of death in patients with rheumatoid arthritis: a population‐based study , 2004, Scandinavian journal of rheumatology.

[13]  F. Wolfe,et al.  Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. , 2004, Arthritis and rheumatism.

[14]  M. Greene,et al.  Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. , 2002, Arthritis and rheumatism.

[15]  S. Gabriel,et al.  Predictors of infection in rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[16]  J. Richert,et al.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. , 2001, Arthritis and rheumatism.

[17]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[18]  T. Osler,et al.  The ICD-9-based illness severity score: a new model that outperforms both DRG and APR-DRG as predictors of survival and resource utilization. , 1998, The Journal of trauma.

[19]  S Shapiro,et al.  Confounding by indication? , 1997, Epidemiology.

[20]  R M Poses,et al.  Controlling for confounding by indication for treatment. Are administrative data equivalent to clinical data? , 1995, Medical care.

[21]  J. F. Fraumeni,et al.  Incidence of cancer among patients with rheumatoid arthritis. , 1993, Journal of the National Cancer Institute.

[22]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[23]  A. Silman,et al.  Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. , 1988, Annals of the rheumatic diseases.